https://scholars.lib.ntu.edu.tw/handle/123456789/461615
標題: | Adjuvant heparanase inhibitor PI-88 therapy for hepatocellular carcinoma recurrence | 作者: | CHUN-JEN LIU Chang J. PO-HUANG LEE Lin D.-Y. Wu C.-C. Jeng L.-B. Lin Y.-J. Mok K.-T. Lee W.-C. Yeh H.-Z. MING-CHIH HO Yang S.-S. Yang M.-D. Yu M.-C. REY-HENG HU Peng C.-Y. Lai K.-L. Chang S.S.-C. PEI-JER CHEN |
公開日期: | 2014 | 出版社: | WJG Press | 卷: | 20 | 期: | 32 | 起(迄)頁: | 11381-11393 | 來源出版物: | World Journal of Gastroenterology | 摘要: | AIM: To demonstrate that administering heparanase inhibitor PI-88 at 160 mg/d is safe and promising in reducing hepatocellular carcinoma (HCC) recurrence for up to 3 year following curative resection. METHODS: A total of 143 patients (83.1% of the 172 participants in the phase II study) participated in the follow-up study. Of these patients, 50 had received no treatment, 48 had received 160 mg/d PI-88, and 45 had received 250 mg/d PI-88 during the phase II trial. Safety parameters and the following efficacy endpoints were investigated: (1) time to recurrence; (2) disease-free survival; and (3) overall survival. RESULTS: PI-88 at 160 mg/d delayed the onset and frequency of HCC recurrence, and provided a clinically significant survival advantage for up to 3 years after treatment compared with those of the control group: (1) the recurrence-free rate increased from 50% to 63%, and (2) time to recurrence at the 36th percentile was postponed by 78%. The efficacy of administering PI-88 at 250 mg/d was confounded by a high dropout rate (11 out of 54 patients). Additionally, subgroup analyses of patients with (1) multiple tumors or a single tumor ? 2 cm; and (2) hepatitis B or C revealed that administering PI-88 at 160 mg/d conferred the most significant survival advantage (56.8% improvement in disease-free survival, P = 0.045) for patients with both risk factors for recurrence. CONCLUSION: Administering PI-88 at 160 mg/d is a safe and well-tolerated dosage that may confer significant clinical benefits for patients with HCC. ? 2014 Baishideng Publishing Group Inc. All rights reserved. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84909630780&doi=10.3748%2fwjg.v20.i32.11384&partnerID=40&md5=86bd6629ff4cd27bfb0096cea38a0ae9 https://scholars.lib.ntu.edu.tw/handle/123456789/461615 |
ISSN: | 1007-9327 | DOI: | 10.3748/wjg.v20.i32.11384 | SDG/關鍵字: | muparfostat; antineoplastic agent; beta glucuronidase; enzyme inhibitor; heparanase; oligosaccharide; phosphomannopentaose sulfate; adult; aged; aminotransferase blood level; Article; bleeding; cancer adjuvant therapy; cancer recurrence; controlled study; disease free survival; drug efficacy; drug safety; female; follow up; hepatitis B; hepatitis C; human; injection site pain; liver cell carcinoma; major clinical study; male; multiple cancer; multiple cycle treatment; neutropenia; overall survival; partial thromboplastin time; patient compliance; phase 2 clinical trial; randomized controlled trial; recurrence free survival; adjuvant chemotherapy; antagonists and inhibitors; Carcinoma, Hepatocellular; clinical trial; drug administration; enzymology; Liver Neoplasms; metabolism; middle aged; mortality; multicenter study; pathology; risk factor; survival; Taiwan; time; treatment outcome; Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Administration Schedule; Enzyme Inhibitors; Female; Glucuronidase; Humans; Liver Neoplasms; Male; Middle Aged; Oligosaccharides; Risk Factors; Survival Analysis; Taiwan; Time Factors; Treatment Outcome |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。